Volume 88 Issue 46 | p. 11 | News of The Week
Issue Date: November 15, 2010

Lilly Adds Imaging Agents

Radiochemistry: Purchase of Avid will bring new Alzheimer’s detection tool
Department: Business
Keywords: radiopharmaceuticals, Alzheimer’s

Eli Lilly & Co. has agreed to acquire Avid Radiopharmaceuticals, a developer of molecular imaging compounds for disease monitoring. The purchase will take the beleaguered drug company into a new market and provide it with a novel tool for developing future drugs.

Lilly will pay $300 million for Philadelphia-based Avid and could make another $500 million in payments to Avid’s owners depending on the future success of florbetapir F 18, the firm’s lead compound. Avid recently asked FDA to approve florbetapir F 18 for detecting amyloid-β, the main component of the plaque found in the brains of Alzheimer’s disease patients.

Avid was founded in 2004 by Daniel M. Skovronsky, who got the idea for the company while completing M.D./Ph.D. and neuropathology programs at the University of Pennsylvania. For help in developing new imaging agents, he turned to one of his advisers, Hank F. Kung, a professor of radiopharmaceutical science at Penn.

Kung says he thought Skovronsky was crazy to turn his back on academia to chase amyloid-β detection. “People were wondering if the whole concept was correct,” he recalls. But Kung signed on and helped Skovronsky come up with florbetapir F 18, which contains radioactive fluorine-18 at the polyether end. When administered, the compound sticks to brain plaque and lights up when scanned by positron emission tomography.

For Lilly, florbetapir F 18 provides entry into the Alzheimer’s disease market after a big setback in August. The company was forced to end development of the Alzheimer’s treatment semagacestat after patients taking it actually fared worse than those taking a placebo. And Lilly needs new products. Stock analysts say the company has the highest exposure to generics competition of any of the big pharma firms (see page 23).

Another plus of the deal, Kung notes, is that Avid’s imaging technology can be broadly integrated into drug development to choose patient populations and track the efficacy of potential treatments. Now in clinical trials at Avid are imaging agents that help detect Parkinson’s disease and diabetes. “Lilly clearly sees the potential of this,” Kung says.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Leave A Comment